Data suggest carfentanil use, deaths rising in Ontario: medical officials

Ontario’s top medical officials say recent statistics suggest a spike in the number of deaths related to the potent opioid carfentanil, as well as an increase in the presence of the drug in the province.

The province’s Chief Medical Officer of Health shared the information with local public health units in a letter last week, encouraging them to raise awareness of carfentanil in the drug supply in their regions.

Dr. David C. Williams says Ontario’s Chief Coroner reports preliminary mortality data show an increase in carfentanil-related deaths in the province for the first four months of this year.

His letter says carfentanil directly contributed to 142 deaths from Jan. 1 to April 29, which amounts to 50 per cent more than the total number of such deaths in all of last year.

It says that number will likely rise as more data from this period become available, since a large proportion of the death investigations from that time are still ongoing.

Williams also says there has been a “sharp” rise in urine samples from LifeLabs that have tested positive for the drug — from up to 100 per month in 2017-2018 to more than 700 each in April and May of this year.

He says the figures are not comprehensive since they only represent those who are getting tested. They also represent results from just one chain of labs, he said, noting that other community and hospital facilities conduct similar tests.

Williams says officials don’t know whether people are using carfentanil, a synthetic fentanyl analogue, intentionally or not.

“Data on carfentanil potency are limited, but best evidence suggests that carfentanil is significantly more potent than fentanyl,” Williams says in the letter.

“Intentional or unintentional carfentanil use could therefore be associated with increased risk of overdose and death compared with use of fentanyl or other opioids.”